{"uid":"cap_peoUPxRgRYjhxgZJrxlc9","slug":"clinicalintelpulse-disease-landscape-3e5cf534","name":"ClinicalIntelPulse Disease Landscape","description":"Competitive drug pipeline landscape for any disease — full Phase 2/3 trial map, mechanism-of-action coverage, approved drugs, PDUFA calendar, M&A activity, opportunity gaps and investment thesis. Worldwide. For biotech and pharma intelligence agents.","url":"https://clinicalintelpulse.vercel.app/api/clinical/disease-landscape","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"depth":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"deal_activity":"Highly active M&A space. AstraZeneca acquired Eccogene NASH program ($185M). Roche/Genentech building liver portfolio. Novo Nordisk GLP-1 dominance creating competitive panic.","query_summary":{"as_of":"2026-06-07","depth":"standard","condition":"NASH (Nonalcoholic Steatohepatitis)"},"approved_drugs":[{"name":"Resmetirom (Rezdiffra)","sponsor":"Madrigal Pharmaceuticals","approved":"2024-03","mechanism":"THR-β agonist","indication":"NASH with moderate-to-advanced fibrosis"}],"pdufa_calendar":[{"drug":"Lanifibranor","sponsor":"Inventiva","mechanism":"Pan-PPAR","pdufa_estimate":"2026-Q1","priority_review":false}],"investment_thesis":"NASH market projected $18-25B by 2030. Resmetirom first approval sets pricing precedent. GLP-1 combination therapy is the likely future standard of care.","opportunity_score":{"max":100,"note":"Validated market with first approval. GLP-1 expansion threatening narrow competitors.","score":78,"rating":"High Value"},"pipeline_overview":{"phase2_count":48,"phase3_count":19,"total_active":67,"approved_drugs":2,"approval_recent_12m":1},"top_phase3_assets":[{"drug":"Semaglutide 2.4mg","nctId":"NCT04858633","sponsor":"Novo Nordisk","mechanism":"GLP-1 RA","completion":"2025-Q4","significance":"Blockbuster potential — NASH + obesity combined label"}],"mechanism_landscape":{"crowded":["FXR agonists (8 Phase 2/3)","ACC inhibitors (6)","FGF21 analogs (5)"],"emerging":["Pan-PPAR agonists","GLP-1/GIP combinations (semaglutide expanding)"],"opportunity_gaps":["Cirrhosis reversal agents","Pediatric NAFLD","Combination sequential therapy protocols"]},"key_readouts_next_18m":["NASH-RESOLVE (semaglutide histology 2025)","MAESTRO-NASH (lanifibranor 2025)","ATLAS trial (aldafermin 2026)"]}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.35","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.35/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.35","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.35","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_mfZ1lriR3OEpmyzJYgIfe","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.35","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns a complete pipeline intelligence snapshot for any disease area, covering Phase 2-3 trial map, mechanism coverage, approved therapies, PDUFA calendar, competitive gaps, and market dynamics.","exampleAgentPrompt":"Give me a full pipeline intelligence report for MASH — I want the Phase 2 and 3 trial map, mechanism coverage, approved landscape, any upcoming PDUFA dates, and where the competitive gaps are.","exampleUseCases":null,"resultDescription":"A structured report covering: active Phase 2/3 trials in the disease area, mechanism-of-action distribution across the pipeline, approved therapy landscape, upcoming PDUFA/regulatory milestones, identified whitespace and competitive gaps, and key sponsor/competitive dynamics.","failureModes":["Unknown or misspelled disease name returns an error or empty results","Very rare or newly-named diseases may have sparse pipeline data","PDUFA calendar may be incomplete if no near-term approvals are pending","Rate limiting or payment failure on the x402 micropayment layer","Stale data if underlying registry sources have not been recently refreshed"],"whenToPreferThis":"Use this endpoint when you need a broad, synthesized intelligence snapshot across an entire disease area in one call — rather than querying individual trial details, single-company pipelines, or specific NCT IDs. Ideal for competitive landscape assessments, investment diligence, BD/licensing scans, or strategic planning where you want Phase 2-3 map, approved drugs, PDUFA dates, and competitive gaps all in one response.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-15T12:46:25.759Z","isFirstParty":false}